These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 17352011

  • 1. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.
    Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG.
    World J Gastroenterol; 2007 Feb 14; 13(6):837-44. PubMed ID: 17352011
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP, Hernández-Rocha C, Morales C, Vargas JI, Solís N, Pizarro M, Robles C, Sandoval D, Ponthus S, Benítez C, Barrera F, Soza A, Riquelme A, Arrese M.
    Gastroenterol Hepatol; 2017 Feb 14; 40(6):388-394. PubMed ID: 28359548
    [Abstract] [Full Text] [Related]

  • 7. Clinical significance of serum Ck18-M65 and M30 levels in patients with chronic hepatitis B combined with nonalcoholic steatohepatitis and liver fibrosis.
    Dai L, Yan Y, Chen Q.
    Medicine (Baltimore); 2024 Jun 07; 103(23):e38342. PubMed ID: 38847670
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P, Rios D, Casciato P, Gadano A, Galdame O, Mullen E, Bertot G, de Matteo E, Preciado MV.
    Eur J Gastroenterol Hepatol; 2018 Jun 07; 30(6):637-644. PubMed ID: 29384795
    [Abstract] [Full Text] [Related]

  • 10. The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease.
    Liang J, Han T, Gao YT, Jing L, Ma Z.
    Eur Rev Med Pharmacol Sci; 2015 Nov 07; 19(21):4123-9. PubMed ID: 26592838
    [Abstract] [Full Text] [Related]

  • 11. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
    Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F.
    J Hepatol; 2014 Jan 07; 60(1):167-74. PubMed ID: 23973932
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S, Stoeckmann N, Geier A, Rau M, Schattenberg JM, Bahr MJ, Manns MP, Jaeckel E, Schulze-Osthoff K, Bantel H.
    Clin Transl Gastroenterol; 2019 Aug 07; 10(8):e00066. PubMed ID: 31397685
    [Abstract] [Full Text] [Related]

  • 14. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
    Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M.
    Dig Dis Sci; 2016 Mar 07; 61(3):905-12. PubMed ID: 26462489
    [Abstract] [Full Text] [Related]

  • 15. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis.
    Lee J, Vali Y, Boursier J, Duffin K, Verheij J, Brosnan MJ, Zwinderman K, Anstee QM, Bossuyt PM, Zafarmand MH.
    PLoS One; 2020 Mar 07; 15(9):e0238717. PubMed ID: 32915852
    [Abstract] [Full Text] [Related]

  • 16. Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines.
    Jamali R, Arj A, Razavizade M, Aarabi MH.
    Medicine (Baltimore); 2016 Feb 07; 95(5):e2630. PubMed ID: 26844476
    [Abstract] [Full Text] [Related]

  • 17. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.
    Mueller S, Nahon P, Rausch V, Peccerella T, Silva I, Yagmur E, Straub BK, Lackner C, Seitz HK, Rufat P, Sutton A, Bantel H, Longerich T.
    Hepatology; 2017 Jul 07; 66(1):96-107. PubMed ID: 28170108
    [Abstract] [Full Text] [Related]

  • 18. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
    Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N.
    J Gastroenterol Hepatol; 2009 Apr 07; 24(4):564-8. PubMed ID: 19378390
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.